Maximum quantity allowed is 999
请选择数量
CAS RN: 70024-40-7 | 产品编码: T2751
产品编码 | T2751 |
纯度/分析方法 | >98.0%(HPLC)(N) |
分子式/分子量 | C__1__9H__2__5N__5O__4·HCl·2H__2O = 459.93 |
外观与形状(20°C) | 固体 |
储存温度 | 室温 (15°C以下阴凉干燥处) |
包装和容器 | 100MG-Glass Bottle with Plastic Insert (查看图片), 1G-Glass Bottle with Plastic Insert (查看图片) |
CAS RN | 70024-40-7 |
相关CAS RN | 63590-64-7&63074-08-8 |
Reaxys-RN | 6495493 |
PubChem物质ID | 125307764 |
MDL编号 | MFCD00941408 |
技术规格
Appearance | White to Almost white powder to crystal |
Purity(HPLC) | min. 98.0 area% |
Purity(with Total Nitrogen) | min. 98.0 % |
Water | 7.0 to 9.0 % |
NMR | confirm to structure |
物性(参考值)
熔点 | 274 °C |
GHS
相关法规
RTECS# | TK8046000 |
运输信息
HS编码* | 2934.99-000 |
应用
Terazosin Hydrochloride: A Long Acting α1-Selective Adrenoceptor Antagonist
Terazosin hydrochloride, a quinazoline derivative, is a long acting α1-selective adrenoceptor antagonist with a similar pharmacodynamic profile to prazosin [P0938]. Terazosin is known to relax vascular and prostate smooth muscle through blockade of α1-adrenoceptors, and lowers blood pressure by decreasing peripheral vascular resistance. In in vitro experiments, terazosin has been shown to contractions in human prostatic tissue, and it is used in the treatment for prostatic hyperplasia (BPH). In addition, some studies indicate that α1-selective adrenoceptor antagonists show suppression of human prostate cancer cell growth. (The product is for research purpose only.)
References
- Adrenergic and serotonergic receptor-blocking potencies of terazosin, a new antihypertensive agent, as assessed by radioligand binding assay
- Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in essential hypertension
- Binding characteristics of naftopidil and α1-adrenoceptor antagonists to prostatic α-adrenoceptors in benign prostatic hypertrophy
- Suppression of human prostate cancer cell growth by α1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis
- Terazosin (The description, physical properties, synthesis, stability, pharmacokinetics, metabolism and analysis of terazosin)
- Validated specific HPLC methods for determination of prazosin, terazosin, and doxazosin in the presence of degradation products formed under ICH-recommended stress conditions
参考文献
TCIMail
产品文档 (部分产品的分析图谱无法提供,敬请谅解。)
化学品安全说明书(SDS)
请选择语言。
如需更多帮助,请联系我 们。
技术规格
CoA及其他文档
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
示例 CoA
可下载CoA示例。注:该示例不一定是最新批次的CoA。
目前没有该产品的 CoA 示例。
分析图谱
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
很抱歉,您搜索的分析图谱无法提供。